References
- Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 2010;464:224–31.
- Kran AM, Sørensen B, Nyhus J, Sommerfelt MA, Baksaas I, Bruun JN, Kvale D. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004;18:1875–83.
- Åsjö B, Stavang H, Sørensen B, Baksaas I, Nyhus J, Langeland N. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res Hum Retroviruses 2002;18: 1357–65.
- Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, . Relative dominance of Gag p24-specific cytotoxic T-lymphocytes is associated with human immunodeficiency virus control. J Virol 2006;80:3122–5.
- Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborn I, Modley E, . CD8 + T-cells response to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46–53.
- Pettersen FO, Tasken K, Kvale D. Combined Env- and Gag-specific T cell responses in relation to PD-1 and CD4 + T cell loss rates in HIV-1 infection. Clin Exp Immunol 2010;161:315–23.
- Sommerfelt MA, Nyhus J, Sørensen B. Novel peptide-based HIV-1 immunotherapy. Expert Opin Biol Ther 2004;4: 349–61.
- Kvale D, Kran AM, Sommerfelt MA, Nyhus J, Baksaas I, Bruun JN, Kvale D. Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia. AIDS 2005;19:563–7.
- Kran AM, Sommerfelt MA, Sørensen B, Nyhus J, Baksaas I, Bruun JN, Kvale D. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine 2005;23:4011–5.
- Kran AM, Sørensen B, Sommerfelt MA, Nyhus J, Baksaas I, Kvale D. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells. AIDS 2006;20:627–30.
- Kran AM, Jonassen TØ, Sommerfelt MA, Løvgården G, Sørensen B, Kvale D. Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides. AIDS 2010;24:2609–18.
- Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, . Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65–78.
- Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, . HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in non-progressors. Nat Immunol 2002;3: 1061–8.
- Day CL, Kiepela P, Leslie AJ, van der Stok M, Nair K, Ismail N, . Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J Virol 2007;81: 434–8.
- Calarota SA, Foli A, Maserati R, Baldantini F, Paulucci S, Young MA, . HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 2008; 180:5907–15.
- Boström AC, Hejdeman B, Matsuda R, Fredriksson M, Fredriksson AL, Bratt G, . Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV). Vaccine 2004;22:1683–91.